⌘K
t
Arecor Therapeutics plc announced on 27 September 2024 that its Chief Executive Officer, Sarah Howell, will provide a live presentation of the Group's interim results for the six months ended 30 June 2024. This presentation will be held via the Investor Meet Company platform on Thursday 3 October at 3pm BST. Questions for a Q&A session can be submitted until 9am BST on Wednesday 2 October 2024, or during the live event.
| Date | 27 Sept 2024 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 9019F |
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company platform
Cambridge, UK, 27 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer, will be providing a live presentation of the Group's recently announced interim results for the six months ended 30 June 2024 via the Investor Meet Company platform, on Thursday 3 October at 3pm BST.
The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard up until 9am BST on Wednesday 2 October 2024, or at any time during the live presentation.
To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:
https://www.investormeetcompany.com/companies/arecor-therapeutics-plc
Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Panmure Liberum Limited (NOMAD and Joint Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG Partners LLP (Joint Broker) |
|
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
|
|
ICR Consilium |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
-